… Lung cancer remains the leading cause of cancer-related death worldwide, with a lower …
Non-small cell lung cancer (NSCLC) represents approximately 85% of lung cancer cases, with …

… : Nivolumab efficacy in patients with non-small-cell lung cancer (NSCLC) and performance
status (PS) of 2-4 is unclear. We aimed to compare survival, treatment efficacy, and safety in …

… for patients with non-small cell lung cancer (NSCLC) (1,2). Despite new treatment options
over the last decade, progress in lung cancer treatment in the broader population has reached …

… lung cancer. The purpose of this study was to conduct a network meta-analysis to compare
the safety and efficacy … methods to evaluate the efficacy and safety of the included treatments. …

… Cancer statistics 2020, lung cancer is the most common one and the leading cause of cancer
… Citation1 Due to the biological characteristics and tumor heterogeneity of lung cancer, it is …

… Considering the especially high risk of VTE for lung cancer, we focused on patients with
lung cancer and included participants from three additional studies for survival analysis.17 ,20 ,…

… Lung cancer remains the leading cause of cancer death worldwide [1]. A majority of lung
cancers can be classified as non-small cell lung cancer (NSCLC), the largest group of which …

… -small-cell lung cancer (NSCLC). Objective: To assess the efficacy and safety of different dose
… The objective of this review is to assess the efficacy and safety of different dose schedules …

… Lung cancer has the highest mortality rate among all cancer types, with a 5-year survival …
Non-small-cell lung cancer (NSCLC) represents roughly 85% of all lung cancer cases [2]. The …

… Lung cancer remains the leading cause of cancer-associated deaths globally. Non-small
cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases [1] and …